Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation
Tessa Goetghebuer, Jerome Le Chenadec, Edwige Haelterman, Luisa Galli, Catherine Dollfus, Claire Thorne, Ali Judd, Olivia Keiser, Jose Tomas Ramos, Jack Levy, Josiane Warszawski, European Infant Collaboration Group, Albert Faye, Stephane Blanche, Clara Gabiano, Diana Gibb, Hannah Castro, Trinh Duong, Carlo Giaquinto, Martina Penazzato, Magdalena Marczynska, Luminita Ene, Victor Babes, Marc Hainaut, Henriette Scherpbier, Uwe Wintergerst, Véronique Schmitz, Bénédicte Brichard, Gwenda Verweel, Pat Tookey, Tessa Goetghebuer, Jerome Le Chenadec, Edwige Haelterman, Luisa Galli, Catherine Dollfus, Claire Thorne, Ali Judd, Olivia Keiser, Jose Tomas Ramos, Jack Levy, Josiane Warszawski, European Infant Collaboration Group, Albert Faye, Stephane Blanche, Clara Gabiano, Diana Gibb, Hannah Castro, Trinh Duong, Carlo Giaquinto, Martina Penazzato, Magdalena Marczynska, Luminita Ene, Victor Babes, Marc Hainaut, Henriette Scherpbier, Uwe Wintergerst, Véronique Schmitz, Bénédicte Brichard, Gwenda Verweel, Pat Tookey
Abstract
The clinical benefit of antiretroviral therapy in infants is established. In this cohort collaboration, we compare immunological and virological response to treatment started before or after 3 months of age. Early initiation provides a better short-term response, although evolution after 12 months of age is similar in both groups.
Source: PubMed